Latest Articles
Welsh health advocate targeted in abusive social media posts - nation.cymru
Welsh health advocate targeted in abusive social media posts nation.cymru
Published: Jan. 22, 2026, 7:01 p.m.
Fruquintinib/Sintilimab Yields Efficacy, Safety in Advanced pMMR Endometrial Cancer - Targeted Oncology
Fruquintinib/Sintilimab Yields Efficacy, Safety in Advanced pMMR Endometrial Cancer Targeted Oncology
Published: Jan. 22, 2026, 4:02 p.m.
Fruquintinib/Sintilimab Yields Efficacy, Safety in Advanced pMMR Endometrial Cancer - targetedonc.com
Fruquintinib/Sintilimab Yields Efficacy, Safety in Advanced pMMR Endometrial Cancer targetedonc.com
Published: Jan. 22, 2026, 4:02 p.m.
Ashiana Ispat Limited Price Targets Raised After Rebound - July 2025 Snapshot & Daily Volume Surge Signals - bollywoodhelpline.com
Ashiana Ispat Limited Price Targets Raised After Rebound - July 2025 Snapshot & Daily Volume Surge Signals bollywoodhelpline.com
Published: Jan. 18, 2026, 7:26 p.m.
Why Does Rina-S Target Folate Receptor Alpha in Endometrial Cancer? - Oncology Nursing News
Why Does Rina-S Target Folate Receptor Alpha in Endometrial Cancer? Oncology Nursing News
Published: Jan. 14, 2026, 7:32 p.m.
Natera Targets Endometrial Cancer With New Signatera Trial, Expanding Its MRD Opportunity - TipRanks
Natera Targets Endometrial Cancer With New Signatera Trial, Expanding Its MRD Opportunity TipRanks
Published: Jan. 14, 2026, 4:33 p.m.
Novel Small Molecule Inhibitors Show Efficacy in Endometrial Cancer - Targeted Oncology
Novel Small Molecule Inhibitors Show Efficacy in Endometrial Cancer Targeted Oncology
Published: Jan. 11, 2026, 4:14 p.m.
Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data - Investing.com UK
Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data Investing.com UK
Published: Jan. 9, 2026, 2:25 p.m.
Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data - Investing.com
Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data Investing.com
Published: Jan. 9, 2026, 1:59 p.m.
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - Sahm
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 …
Published: Jan. 9, 2026, 6:18 a.m.
Link copied to clipboard!